By Pat Anson, Editor
An FDA decision to block a generic version of OxyContin from coming on the market is a “clear mandate” that other opioid painkillers will have to be made tamper resistant, according to the head of the German pharmaceutical company that developed the technology that makes it harder for pills to be crushed and abused.
“My personal view is this is a precedent on how the FDA will move on other (drug) molecules,” Harald Stock, CEO of Grunenthal Group, told the National Pain Report. Grunenthal licensed its abuse-deterrent technology to Purdue Pharma, which began using it in OxyContin in 2010.
On Tuesday, the Food and Drug Administration approved new labeling for OxyContin stating that the reformulated version of the painkiller is harder to crush or dissolve and reduces chances of abuse. It’s the first time the FDA has recognized the effectiveness of a tamper-resistant product.
Read more at National Pain Report.
(0) Readers Comments
November 12, 2012
October 08, 2012
September 12, 2012
June 04, 2018
June 04, 2018
June 01, 2018
Wow! This could be one particular of the more helpful blogs I've acros
Thank you so much for the great article, it was fluent and to the poin
Having been a customer of the enterprise marketing automation systems
I writing them up in Assignments first and then I update the blog and
In July of 2015, it was discovered that I had type 2 diabetes. By the